TC
DMAC icon

Truvestments Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Truvestments Capital’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.3K Hold
9,849
– – 0.01% 476
2026
Q1 		$66.7K Hold
9,849
– – 0.01% 460
2025
Q4 		$78.4K Buy
9,849
+5,210
+112% +$39K 0.01% 381
2025
Q3 		$31.9K Buy
4,639
+627
+16% +$3.4K 0.01% 512
2025
Q2 		$15.6K Buy
+4,012
New +$15.6K ﹤0.01% 581

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Truvestments Capital's DMAC Position: Q2 2026 in Review

Truvestments Capital held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 9,849 shares worth $69.3K. The position accounts for 0.01% of the portfolio, ranked #476.

Truvestments Capital first reported a position in DMAC in Q2 2025 and has held it in 5 quarters since. The position peaked at $78.4K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Truvestments Capital held 9,849 shares of DiaMedica Therapeutics worth $69.3K as of Q2 2026.
  • Truvestments Capital left its DiaMedica Therapeutics share count unchanged in Q2 2026.
  • DiaMedica Therapeutics made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #476 holding.
  • Truvestments Capital first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Truvestments Capital's DiaMedica Therapeutics position peaked at $78.4K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.